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Protocol
AbstrACt
Musculoskeletal shoulder problems are common after 
breast cancer treatment. Early postoperative exercises 
targeting the upper limb may improve shoulder function. 
This protocol describes a National Institute for Health 
Research-funded randomised controlled trial (RCT) to 
evaluate the clinical and cost-effectiveness of an early 
supervised structured exercise programme compared with 
usual care, for women at high risk of developing shoulder 
problems after breast cancer surgery.
Methods This pragmatic two-armed, multicentre RCT is 
underway within secondary care in the UK. PRevention Of 
Shoulder ProblEms tRial (PROSPER) aims to recruit 350 
women from approximately 15 UK centres with follow-
up at 6 weeks, 6 and 12 months after randomisation. 
Recruitment processes and intervention development were 
optimised through qualitative research during a 6-month 
internal pilot phase. Participants are randomised to the 
PROSPER intervention or best practice usual care only. The 
PROSPER intervention is delivered by physiotherapists and 
incorporates three main components: shoulder-specific 
exercises targeting range of movement and strength; 
general physical activity and behavioural strategies to 
encourage adherence and support exercise behaviour. The 
primary outcome is upper arm function assessed using 
the Disabilities of the Arm, Shoulder and Hand (DASH) 
questionnaire at 12 months postrandomisation. Secondary 
outcomes include DASH subscales, acute and chronic 
pain, complications, health-related quality of life and 
healthcare resource use. We will interview a subsample 
of 20 participants to explore their experiences of the trial 
interventions.
Discussion The PROSPER study is the first multicentre 
UK clinical trial to investigate the clinical and cost-
effectiveness of supported exercise in the prevention 
of shoulder problems in high-risk women undergoing 
breast cancer surgery. The findings will inform future 
clinical practice and provide valuable insight into the role 
of physiotherapy-supported exercise in breast cancer 
rehabilitation.
Protocol version Version 2.1; dated 11 January 2017
trial registration number ISRCTN35358984; Pre-results.
bACkgrounD  
Breast cancer is the most common cancer 
in women in the UK with a 30% increase 
in incidence since the early 1970s.1 Due to 
advances in screening and treatment, the 
survival rate has progressively risen and 
now two-thirds of women will survive for 20 
years beyond their breast cancer diagnosis.1 
The mainstay treatment is surgery to the 
breast and axilla, supplemented with chemo-
therapy, radiotherapy (RT) and endocrine 
therapy, depending on tumour stage and 
other clinical criteria. As a consequence of 
these treatments, upper limb problems such 
as decreased shoulder range of movement 
(ROM), impaired strength, chronic pain, 
sensory disturbances and lymphoedema are 
common adverse treatment effects.2 3 Studies 
suggest that up to 67% of women have arm or 
shoulder symptoms up to 3 years after treat-
ment.4 Persistent upper limb dysfunction and 
pain are debilitating, have a negative impact 
on sleep, quality of life, physical functioning 
and emotional well-being. Given successes 
in increasing survival, it is timely to identify 
strengths and limitations of this study
 ► A large pragmatic study delivering a complex inter-
vention to prevent postoperative health problems in 
patients with newly diagnosed cancer within sec-
ondary care.
 ► A strength of the evaluation is the mixed methods 
approach incorporating embedded qualitative re-
search and economic analysis.
 ► Recruited participants undergo multiple cancer 
treatments, thus experience a complicated postop-
erative recovery pathway.
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strategies to improve the health-related quality of life of 
women after breast cancer treatment.
Several risk factors for shoulder and upper body 
problems after breast cancer treatment have been iden-
tified, including treatment-related factors, such as type 
of axillary surgery and RT, and patient factors such as 
age, body mass index (BMI) and pre-existing shoulder 
problems.4 5 Women undergoing mastectomy compared 
with breast conserving surgery are at greater risk of 
postoperative shoulder restrictions (OR 5.7, 95% CI 
1.03 to 31.2).4 Additionally, those undergoing axillary 
lymph node clearance (ANC) are at greater risk of post-
operative arm complaints compared with those having 
sentinel lymph node biopsy (OR 9.8; 95% CI 3.5 to 
27.5).4–6 RT, particularly to the axilla or chest wall, 
increases the odds of shoulder restriction (pooled OR 
1.7, 95% CI 1.0 to 2.9) and lymphoedema (pooled OR 
1.5, 95% CI 1.2 to 1.8) compared with women treated 
without adjuvant RT.4 Women reporting problems in the 
upper body and shoulder region before surgery are also 
at increased risk of chronic postoperative pain.5 7 BMI 
at time of surgery has been shown to have an indepen-
dent negative effect on shoulder external rotation up to 
7 years after breast cancer treatment, and increased BMI 
is a risk factor for chronic postoperative pain and arm 
lymphoedema.7 8 It is important that the UK National 
Health Service (NHS) provides optimal care for these 
women at high risk of developing shoulder problems 
to ensure recovery and return to usual activities after 
cancer treatment.
A Cochrane review identified 24 studies (2132 
participants) investigating exercise following breast 
cancer surgery.9 Six studies (n=354), conducted 
outside of the UK, found that structured postoperative 
exercise significantly improved shoulder ROM in the 
short term and long term when compared with usual 
care.9 Ten studies (n=1304) have evaluated timing of 
exercise delivery; programmes initiated immediately 
postoperatively (1–3 days) versus delayed exercise 
suggest that early postoperative exercise does signifi-
cantly improve long-term shoulder ROM. However, 
some studies reported an increased risk of wound-re-
lated complications with early exercise, such as seroma 
and surgical site infection.9 The largest UK trial to 
date (n=116 patients), published after the Cochrane 
review, found that participants were less likely to 
develop lymphoedema when exercises were limited 
to 90° of shoulder elevation during the first postop-
erative week compared with those performing unre-
stricted exercises.10 These previous trials investigating 
the efficacy of exercise following breast cancer surgery 
have been criticised for being of poor methodological 
quality and for omitting important patient-reported 
outcomes such as function and health-related quality 
of life.9 Furthermore, there is ongoing uncertainty 
around the optimal type, dose and timing of exer-
cise after breast cancer treatment. Moreover, none 
of the trials conducted to date has investigated the 
cost-effectiveness of structured exercise programmes 
after breast cancer treatment.
rationale for a trial
To date, no large-scale, high-quality, multicentre 
randomised controlled trial (RCT) investigating the clin-
ical effectiveness of a structured physiotherapy interven-
tion compared with usual care for women undergoing 
breast cancer surgery has been conducted. Given the 
lack of knowledge regarding the intensity and duration 
of exercise interventions after breast cancer surgery, 
this trial will provide evidence on whether a rigorously 
designed physiotherapy-led intervention, incorporating 
behaviour change theory, improves postoperative func-
tion and related outcomes, and whether this is cost-effec-
tive to deliver in the NHS setting.
MethoDs
Aim
The overall aim of PRevention Of Shoulder Prob-
lEms tRial (PROSPER) is to investigate the clinical 
and cost-effectiveness of an early supervised exercise 
programme compared with best practice usual care for 
women at high risk of shoulder problems after treat-
ment for breast cancer, on outcomes of upper arm 
function, complications and quality of life. Specific trial 
objectives are:
1. To develop and refine a complex intervention of 
physiotherapy-led exercise for women at risk of devel-
oping musculoskeletal problems after breast cancer 
treatment;
2. To assess the acceptability of the structured exercise 
programme and outcome measures, optimise partic-
ipant recruitment and refine trial processes during a 
6-month internal pilot phase at three clinical centres;
3. Use findings from the internal pilot phase to under-
take a definitive full RCT in approximately 15 UK 
NHS breast cancer centres.
This protocol follows guidance from the Standard 
Protocol Items: Recommendations for Interventional 
Trials (SPIRIT).11 Core trial information is presented 
in table 1. Figure 1 as per SPIRIT guidance, details the 
schedule of enrolment, interventions and assessment.
trial design and setting
A multicentre, pragmatic, parallel, two-arm RCT with 
an internal pilot study and embedded economic evalua-
tion and qualitative studies. The trial framework is supe-
riority rather than equivalence or exploratory. The trial 
is currently open and recruiting from 17 NHS tertiary 
breast cancer centres across England. Participants are 
randomised in a 1:1 ratio between intervention and 
control arms.
Patient and public involvement in trial design
Four female patient and public involvement (PPI) repre-
sentatives, all of whom were treated for breast cancer, 
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were consulted during the initial grant preparation, inter-
vention development and trial set up. Our PPI represen-
tatives contributed to the design of the intervention and 
advised on recruitment-related issues; they provided valu-
able insight into the worries and concerns experienced 
during cancer treatment.
eligibility criteria
Women are eligible to participate in PROSPER if they 
are: diagnosed with histologically confirmed invasive or 
non-invasive primary breast cancer scheduled for surgical 
excision; aged 18 years or over; can comply with the 
protocol; willing to provide written informed consent and 
considered as being at high risk of developing postoper-
ative shoulder problems (table 2). This is a pragmatic 
trial and it is important that inclusion criteria reflect 
contemporary clinical practice. Therefore, women are 
also eligible where a later decision is made for postoper-
ative RT to the axilla and/or supraclavicular region, thus 
changing their risk status from low to high. ‘Late entry’ 
women are eligible for the trial if the decision for postop-
erative RT is made within 6 weeks of surgery. Women who 
have had previous breast surgery (such as excision of a 
benign tumour or breast cyst) and those women who have 
had previous contralateral (opposite side) mastectomy, 
are eligible for invitation providing they fulfil high-risk 
criteria for shoulder problems. Women having immediate 
reconstruction or bilateral breast surgery are ineligible as 
the usual NHS postoperative care pathway often includes 
routine postoperative physiotherapy. Exclusion criteria 
are presented in table 2.
Participant screening, recruitment and consent
Participants are screened and identified from multi-
disciplinary team meetings and preoperative breast/
oncology clinic lists in secondary care. The initial 
screening process is undertaken by a member of the 
clinical team, research nurse or trained designee. 
Potentially eligible patients are approached by clinical 
or research staff and are given a patient information 
sheet with further explanation of the trial. Figure 2 
summarises participant flow.
Table 1 WHO trial registration data set
Data category Information
Primary registry 
and trial identifying 
number
ISRCTN35358984
Date of registration 
in primary registry
Project number 13/84/10
Secondary 
identifying numbers
Health Technology Assessment (HTA)
Source of monetary 
or material support
National Institute for Health Research, 
HTA
Joint sponsor University of Warwick/
University Hospitals Coventry and 
Warwickshire NHS Trust
Contact for public 
queries
prosper@warwick.ac.uk
Contact for scientific 
queries
Professor Julie Bruce, Warwick 
Clinical Trials Unit, University of 
Warwick
Public title Exercise to prevent shoulder problems 
in patients undergoing breast cancer 
treatment
Scientific title The PRevention Of Shoulder 
ProblEms tRial: a randomised 
controlled clinical trial comparing 
physiotherapy-led exercise vs usual 
care in women at high risk of shoulder 
problems after breast cancer surgery
Countries of 
recruitment
UK
Health condition or 
problem studied
Breast cancer
Interventions Advice only: breast cancer care 
leaflets
Comparator: physiotherapy-led 
structured exercise programme 
incorporating behavioural strategies
Key inclusion and 
exclusion criteria
Age: 18 years or over, no upper age 
restriction
Sex: female
Inclusion: confirmed invasive/non-
invasive primary breast cancer 
schedule for surgical excision, at high 
risk of shoulder problems as defined 
by criteria given in table 2
Exclusion: males, and women with 
exclusion criteria as described in 
table 2.
Study type Interventional
Allocation: randomised; individual 
assignment
Primary purpose: prevention
Phase III
Date of first 
enrolment
January 2016
Target sample size 350
Continued
Data category Information
Recruitment status Recruiting to July 2017
Primary outcome Arm, shoulder and hand function as 
measured using the Disabilities of 
the Arm, Shoulder and Hand (DASH) 
questionnaire at 12 months
Key secondary 
outcomes
DASH subscales, pain (acute, 
chronic, neuropathic), health-
related quality of life, surgical site 
infection, lymphoedema and other 
complications, healthcare resource 
use. Exercise/activity data to inform 
adherence to interventions
Table 1 Continued 
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Allocation sequence generation and randomisation
Randomisation is based on a computer-generated algo-
rithm held and controlled centrally by the Warwick 
Clinical Trials Unit (WCTU) programming team, 
independent from the PROSPER team. The WCTU 
telephone randomisation service is used whereby 
randomisation occurs after eligibility and informed 
consent has been obtained. Concealment of alloca-
tion is maintained. An automated confirmation email 
of intervention allocation is generated to the study 
team. Randomisation is stratified by the following vari-
ables: (i) first versus repeat surgery; (ii) centre and (iii) 
whether informed of the need for RT within 6 weeks 
of surgery. The first variable adjusts for the require-
ment for any additional surgery which may change risk 
status from low to high (eg, second procedure ANC or 
re-excision of surgical margins). The second stratifica-
tion variable ensures balanced allocation across each 
recruitment site. The third variable accounts for late 
entry to the trial, thus relates to the timing of interven-
tion delivery and whether participants are randomised 
preoperatively (up to the day of surgery) or within the 
first 6 weeks postoperatively. Due to the nature of the 
study intervention, it is not possible to blind partici-
pants or treating physiotherapists to treatment alloca-
tion. However, receipt and handling of outcome data 
collection is blinded, thus data entry of returned postal 
questionnaires, data cleaning and interim statistical 
analyses are conducted without knowledge of treatment 
allocation (blinded).
InterventIons
Control arm: usual care
All participants allocated to the usual care arm receive 
best practice usual care in the form of written leaflets 
containing information about exercises, recovery after 
surgery and treatments for breast cancer. During the 
pilot phase, different exercise information leaflets were 
reviewed and considered; we also consulted best practice 
guidance for written patient information materials.12 The 
most commonly used information leaflets were ‘Exercises 
after Breast Cancer Surgery (BCC6)’ and ‘Your Opera-
tion and Recovery (BCC151)’ published by Breast Cancer 
Care (BCC).13 The BCC leaflets were selected because of 
content, style and clarity of presentation of information. 
Figure 1 Study outcome measures and assessment time points. PROSPER, PRevention Of Shoulder ProblEms  tRial. 
Table 2 Trial inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years Males
Histologically confirmed invasive 
or non-invasive primary breast 
cancer scheduled for surgical 
excision of breast cancer
Women having 
immediate reconstructive 
surgery
Considered high risk of 
developing shoulder problems 
after surgery defined by one or 
more of the following:
 ► Planned axillary node clearance
 ► Planned radiotherapy to the 
axilla and/or supraclavicular*
 ► Existing shoulder problems 
(based on PROSPER screening 
criteria)
Women having SLNB, 
with or without breast 
surgery, unless they fulfil 
other high-risk criteria
Obesity defined as body mass 
index >30
Women having bilateral 
breast surgery
Any subsequent axillary surgery 
related to primary surgery, eg, 
axillary lymph node clearance 
conducted after SLNB
Evidence of metastatic 
disease at time of 
recruitment
Able to provide written informed 
consent
Willing and able to comply with 
the protocol
*Includes women informed of need for radiotherapy to the axilla 
and/or supraclavicular within 6 weeks of surgery, thus potential late 
entry to the trial is allowed in this setting.
PROSPER,  PRevention Of Shoulder ProblEms tRial; 
SLNB, sentinel lymph node biopsy.
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These two information leaflets were given to all patients 
before surgery by breast care nurses, or other healthcare 
professionals, depending on local practice.
Intervention arm: ProsPer exercise programme
Participants randomised to the active intervention 
receive usual care leaflets in addition to the PROSPER 
intervention: a structured individualised exercise 
programme, comprising a minimum of three face-to-face 
and maximum of six sessions or contacts with a physio-
therapist. As per Medical Research Council and TiDieR 
guidance, a more detailed description of the interven-
tion development and final content has been described 
separately (submitted for publication). We selected 
exercises and components based on systematic reviews 
and clinical guidelines. A Cochrane review investigated 
the effectiveness of exercise interventions in preventing, 
minimising or improving upper-limb dysfunction due to 
breast cancer treatment.9 This review included 24 trials 
and classified exercise type as active, active-assisted, passive 
ROM, manual stretching, active stretching and resistance 
exercises. We considered these components in relation to 
evidence of effectiveness on shoulder ROM and strength. 
This process was also augmented by eliciting opinions 
from clinical experts in the field of cancer rehabilitation 
and health psychology. The final PROSPER programme 
Figure 2 Trial flow diagram. DASH, Disabilities of the Arm, Shoulder and Hand; MDT, multidisciplinary team; 
PROSPER, PRevention Of Shoulder ProblEms  tRial; QoL, quality of life. 
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comprises specific exercises targeting shoulder range of 
motion and upper arm muscle strength, general physical 
activity and behavioural adherence strategies.
Overview of exercise intervention
The intervention is predominantly delivered in physio-
therapy outpatient departments. The first physiotherapy 
session is arranged 7–10 days after surgery, for assess-
ment of shoulder ROM, postoperative pain, function, 
arm swelling, patients’ goals and assessment of confi-
dence to carry out prescribed exercises. Participants 
are prescribed an individually tailored home exercise 
programme and provided with guidance on rehabilita-
tion, management of postoperative complications and 
returning to general physical activity and/or work. The 
intervention targets three movement directions using 
a combination of active-assisted ROM, active ROM and 
stretches: shoulder flexion (forward), shoulder abduc-
tion (side) and abduction with external rotation (open 
chest). The second appointment is between 4–6 weeks 
postoperatively to review progress and prescribe shoulder 
strengthening exercises. The programme is progressed 
by increasing exercise repetitions, sets and resistance. 
The third appointment is recommended for between 12 
and 16 weeks postoperatively, for further progression to 
facilitate return to work, sport and hobbies. For women 
with later entry on the basis of postoperative RT, these 
timings will be slightly delayed, but the prescribed exer-
cise programme should commence at the earliest oppor-
tunity, thus within 6 weeks of surgery.
As per development work with patient representa-
tives, and to reflect the pragmatic trial design, three 
additional physiotherapy consultations are available on 
request. The timing and delivery of additional appoint-
ments, either via telephone or face-to-face, are flexible 
to account for ongoing treatment, physiotherapist judge-
ment and patient preference. Ideally, the intervention 
will be completed within the first 6 months following 
surgery, but women can contact their physiotherapist 
for up to 12 months after randomisation. Thus, any late 
treatment-related shoulder problems will be dealt with 
by the trial physiotherapist. Number and method of 
physiotherapy contacts will be closely monitored during 
the trial.
outCoMes
Figure 1 and table 3 present the study outcome measures 
and standardised assessment scales by assessment time 
point. Questionnaires are completed at baseline on 
recruitment, then at 6 weeks, 6 and 12 months after 
randomisation by post. The primary outcome is upper 
limb function at 12 months measured using the Disabili-
ties of Arm, Shoulder and Hand (DASH) questionnaire.14 
We considered other patient-reported outcome measures, 
including shoulder-specific scales, however selected the 
DASH because it captures symptoms and function of the 
upper limb rather than the shoulder joint per se. There is 
good evidence to suggest that women experience a variety 
of difficulties and restrictions after breast cancer treat-
ment, affecting the hand, arm and shoulder. Functional 
impairment to the arm can affect performance of simple 
daily activities, including writing, opening or closing jars, 
lifting and/or holding shopping bags.
The DASH is a 30-item patient-reported outcome measure 
designed to capture difficulty in performing various upper 
arm activities.14 15 A single DASH score is generated, 
although psychometric assessment using discriminant 
content validation analysis has shown that the scale can be 
used to produce three health outcome subscores for impair-
ment, activity limitation and participation restriction, as 
per the WHO International Classification of Functioning 
Disability and Health taxonomy.16
Table 3 Outcome assessment
Outcome Domain Scale/measure
T0
baseline
t1
6 weeks
t2
6 months
t3
12 months
Primary Function DASH √
Secondary Function DASH subscales √ √ √
Acute and 
chronic pain
Neuropathic pain
FACT-B4; NRS 
DN4
√
√
√
√
√
√
√
√
Complications SSI+self-report √ √ √
Lymphoedema Self-report √ √ √ √
Health-related 
QoL
SF12/EQ-5D-5L √ √ √
Resource use Self-report √ √
General activity 
and exercise
PASE items √ √ √ √
DASH, Disabilities of Arm, Shoulder and Hand questionnaire; DN4, Doleur Neuropathique; EQ-5D-5L, Euroqol; FACT-B4, Functional 
Assessment of Cancer Therapy-Breast; NRS, numerical rating scale; PASE, Physical Activity Scale for the Elderly; QoL, quality of life; SF12, 
Short Form-12; SSI, surgical site infection; t, time point.
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secondary outcomes
Secondary outcomes include health-related quality of life 
(EuroQol EQ-5D-5L and Short-Form-12), DASH subscores 
and surgical adverse events including pain (acute, chronic, 
neuropathic pain) surgical site infection and lymphoedema 
as per table 3. A numerical rating scale 0–10 and Doleur 
Neuropathique Questionnaire are used to collect pain 
intensity and pain character. The Functional Assessment 
of Cancer Therapy-Breast subscale captures arm tender-
ness, numbness, painful movement and stiffness. We added 
items to capture arm heaviness and swelling as self-report 
indicators of lymphoedema. Data on exercise/mobility 
are collected to allow comparisons in physical activity 
(selected items from the Physical Activity Scale for the 
Elderly (PASE)). The PASE was designed for use with older 
adults has been validated for use in clinical trials recruiting 
patients aged 55 years and older.17 Healthcare resource use 
is recorded for economic analyses.
sAMPle sIze
PROSPER aims to recruit 350 patients, allocated in a 1:1 
ratio. The sample size calculation is based on a Dutch trial 
of 30 women with breast cancer, randomised to physio-
therapy over a 3-month period, reporting a between-group 
difference of 7 points on the DASH at 6 months.18 At 80% 
power and P<0.05, this yields a target of 242 participants in 
total. Accounting for therapist effects, an intracluster coeffi-
cient (ICC) of 0.01 (yielding a design effect of 1.05), gives a 
target of 256 participants. The ICC estimate is based on our 
previous experience of exercise interventions in a range 
of musculoskeletal trials. We anticipate loss to follow-up of 
<10% based on our previous clinical trials however, have 
inflated this to 25% to cover the possibility that numbers 
lost to follow-up are greater than anticipated, for example, 
due to ongoing cancer treatment.
The study is powered to detect a 7-point difference on the 
DASH. Studies of rheumatological and orthopaedic popula-
tions have suggested that the minimally clinically important 
difference for the DASH is 10, and that the between-group 
difference for trials should be set at 10.19 However, this 
fails to account for many of the eventualities that occur in 
pragmatic trials, notably that there is not a ‘no treatment’ 
control arm, and therefore that some of the control group 
may be exposed by serendipity to an intervention of similar 
intensity, particularly in a high-risk population.
Internal pilot study
A 6-month internal pilot phase was conducted at three 
breast cancer units (Coventry, Oxford and Wolver-
hampton) to evaluate processes for patient identifica-
tion, eligibility and refinement of recruitment estimates. 
The intended sample size for the internal pilot study was 
30 participants, approximately 10% of the full sample. 
Acceptability of the PROSPER intervention was explored 
through qualitative research involving audio-recorded 
individual interviews with seven participants. Changes 
were made to patient-facing materials and to exercise 
intervention materials. Easy-to-use pocket-sized lami-
nated cards with details of inclusion/exclusion criteria 
and shoulder screening criteria were produced for 
recruitment staff. Additional telephone or face-to-face 
appointments were added to the exercise intervention 
to allow for flexibility during ongoing cancer treatment. 
Data from the pilot phase helped to refine recruitment 
and trial processes. Patients recruited to the pilot phase 
continue with the follow-up schedule and will be retained 
in the full trial analysis. The pilot study was completed 
as planned and the funder approved progression to full 
trial.
Data analysis
Statistical analysis will be intention-to-treat and will 
comply with the Consolidated Standards of Reporting 
Trials (CONSORT) guidelines. The primary outcome 
data will be summarised using mean, SD, median and 
range values. The clustering effect will be assessed prior to 
analysis of the data. In the presence of a clustering effect, 
the primary outcome will be analysed using multilevel 
linear regression models. If there is negligible clustering 
effect, it will be analysed using ordinary linear regres-
sion models. In each case, the mean change from base-
line (to 6 and 12 months) will be summarised for each 
of the treatment arms and differences between the inter-
ventions using unadjusted and adjusted (for age, type 
of surgery and RT) estimates. These mean changes and 
their 95% CIs will be plotted graphically so that change 
can be assessed over the course of the study. Continuous 
secondary outcomes will be assessed in a similar way to the 
primary outcome. Categorical data will be analysed using 
random effect/ordinary logistic models, depending on 
the presence of a clustering effect.
A DASH score cannot be computed if there are more 
than three missing items. As a sensitivity analysis, the 
impact of missing data will be assessed using multiple 
imputation. The impact of non-compliance with the 
intervention will be examined using the complier average 
causal effect (CACE) analysis.20 21 We have reviewed 
definitions of compliance for CACE analyses used in 
other therapy trials.22 23 Complete compliance with the 
PROSPER intervention is defined as having three or 
more contacts with the PROSPER therapist; an additional 
analysis will be undertaken to explore partial compliance, 
defined as less than three sessions. Analyses and template 
tables will be reported in a detailed statistical analysis 
plan for review and approval by the Data Monitoring 
Committee (DMC), prior to final statistical analysis of the 
data. Planned sensitivity analyses include: a) the impact of 
low/high recruitment centres on clustering effect and b) 
assessment of differences between date of randomisation 
and date of surgery across groups, as surgical trials vary in 
relation to timing of follow-up.
Economic evaluation
The primary economic evaluation will be conducted 
from the NHS and personal social services perspective24 
 o
n
 26 Novem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019078 on 23 March 2018. Downloaded from 
8 Bruce J, et al. BMJ Open 2018;8:e019078. doi:10.1136/bmjopen-2017-019078
Open Access 
using the intention-to-treat approach.25 Data will be 
collected on the health and social service resources used 
in the treatment of each trial participant from randomis-
ation to 12 months postrandomisation. Primary research 
methods will be used to estimate the costs of delivering 
the physiotherapy-led exercise programme, including 
development and training of accredited providers, the 
cost of delivering the individual sessions and participant 
monitoring activities. Broader resource utilisation will be 
captured through three main sources: (i) clinical data 
extraction forms; (ii) patient postal questionnaires at 6 
and 12 months postrandomisation; and if feasible within 
the trial timeline, (iii) routine health data sources from 
NHS Digital. Current UK unit costs will be applied to 
each resource item to estimate costs in each trial arm. 
Health-related quality of life will be measured at base-
line and at 6 and 12 months postrandomisation using 
the generic EQ-5D-5L and SF-12 measures; national tariff 
sets will be used to generate quality-adjusted life-years 
(QALYs).26–30
An incremental cost-effectiveness analysis, expressed 
in terms of incremental cost per QALY gained, will be 
performed. Detailed methods of analysis will be prespec-
ified within a health economics analysis plan approved 
by the trial team prior to analysis to ensure appropriate 
methods are used. Results will be presented using incre-
mental cost-effectiveness ratios (ICERs) and cost-effec-
tiveness acceptability curves generated via the net-benefit 
framework. A series of sensitivity analyses will be under-
taken to explore the implications of uncertainty on the 
ICERs and to consider the broader issue of the generalis-
ability of the study results. Due to the known limitations 
of within-trial economic evaluations,31 a decision-analyt-
ical model may be constructed to examine the long-term 
costs and outcomes beyond the end of the trial. Costs 
and outcomes beyond the first year will be discounted to 
present values24 and probabilistic sensitivity analyses will 
be undertaken to explore the impact of uncertainty on 
the ICERs.
Qualitative substudy
An embedded qualitative study will be undertaken to 
gain insight into the experiences of women participating 
in trial interventions. We will explore the acceptability of 
the exercise programme and compare and contrast expe-
riences with women allocated to the control intervention.
Design of substudy
In-depth, semi-structured interviews will be conducted 
and audio-recorded. Interview topic guides will be used to 
ensure similar areas are covered in each interview. Partic-
ipants consenting to the main trial are asked to indicate 
willingness to take part in a future interview to explore 
postoperative experiences. A total of 20 interviews are 
planned, with 10 women from each intervention arm. 
Purposive sampling will be used, striving for a mix of 
geographical location, age, employment status, socioeco-
nomic background and ethnicity.
Analysis
Interviews will be recorded, transcribed and analysed using 
a Framework Approach. A thematic framework will be 
developed using predetermined themes plus new themes 
raised by participants. The framework will be applied to 
the interview text and coded data will be arranged on a 
chart according to each theme identified. Themes will be 
examined with a view to providing explanations of the 
participants’ experiences and understandings.
Data security and management
Participant data are stored on a secure database in accor-
dance with the Data Protection Act (1998). A unique trial 
identification number is used on all participant commu-
nication. Clinical and patient forms are being checked 
for completeness and congruity before data entry onto 
the PROSPER database. Data will undergo additional 
checks to ensure consistency between data submitted 
and original paper forms. Trial documentation and data 
will be archived for at least 10 years after completion of 
the trial in accordance with WCTU standard operating 
procedures.
trial monitoring
The Trial Management Group will oversee all aspects of 
design, delivery, quality assurance and data analysis. A 
Trial Steering Committee (TSC), with independent Chair-
person, will monitor the trial at least once per year. An 
independent DMC will review trial progress, recruitment, 
protocol compliance and interim analysis of outcomes, 
annually or more frequently as requested. Recruitment 
data from the internal pilot study were reviewed by inde-
pendent committees and by the funder to approve the 
launch of the main trial.
Adverse event management
A safety reporting protocol has been developed for 
related and unexpected serious adverse events and 
directly attributable adverse events (AEs). An AE is 
defined as any untoward medical occurrence in a subject 
which does not necessarily have a causal relationship with 
the intervention. Any AE that occurs while undertaking 
PROSPER exercises, either during an appointment, or 
while exercising unsupervised at home, require reporting 
to the trial team. The trial Chief Investigator, with input 
from the WCTU Quality Assurance team, determine 
whether AEs require reporting to the trial sponsor, DMC 
and Ethics Committee, in accordance with the full safety 
reporting protocol.
Dissemination policy
The study team are committed to full disclosure of the 
results of the trial. Findings will be reported in accor-
dance with CONSORT guidelines32 and we aim to publish 
in high impact journals. Our patient representatives 
will assist with dissemination of study results through 
INVOLVE, other cancer patient groups and organisations 
including www. independent canc erpa tien tsvo ice. org . uk. 
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The funder will take no role in the analysis or interpreta-
tion of trial results.
DIsCussIon
PROSPER will be the largest UK RCT examining the effec-
tiveness of an early, supervised exercise and behavioural 
support intervention for women at risk of developing 
shoulder problems after breast cancer surgery. Previous 
trials in this field have been criticised for being of poor 
methodological quality and lacking in important outcome 
measures, such as patient-reported shoulder function 
and health-related quality of life. Another challenge 
encountered in previous clinical trials of this population 
is low participant recruitment, partly due to the short 
time frame between diagnosis and surgery and perhaps 
compounded by reluctance to undertake active exercise 
when faced with a distressing and potentially life-threat-
ening cancer diagnosis. PROSPER aims to recruit 350 
patients with newly diagnosed breast cancer to provide 
empirical data on whether a physiotherapy-led exercise 
programme is effective for reducing shoulder disability, 
when delivered in a pragmatic NHS clinical setting. The 
design and development of this complex intervention 
was underpinned by multiple stages of work, in line with 
MRC guidance on the development of complex interven-
tions. A full description of the content of the PROSPER 
exercise intervention has been submitted elsewhere for 
publication.
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